Oct 26 (Reuters) – Merck & Co Inc: * KEYTRUDA® (PEMBROLIZUMAB) AS MONOTHERAPY REDUCED THE RISK OF DISEASE PROGRESSION OR DEATH BY 43% FOR CERTAIN PATIENTS WITH ADVANCED OR RECURRENT ENDOMETRIAL CANCER
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)